Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2022 08:03 ET | Source: Codex DNA, Inc.

Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA

SAN DIEGO, April 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the completion of proof-of-concept...
April 18, 2022 15:47 ET | Source: Codex DNA, Inc.

Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington 2022

SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker presentation for the World...
April 06, 2022 08:03 ET | Source: Codex DNA, Inc.

Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta’s Built with Biology Global Conference

SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at...
March 22, 2022 16:05 ET | Source: Codex DNA, Inc.

Codex DNA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Guidance

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and...
March 03, 2022 08:03 ET | Source: Codex DNA, Inc.

Codex DNA Announces Registration and Webcast Information for Upcoming R&D Webinar on March 29, 2022

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced details for its first Investor R&D...
March 02, 2022 08:03 ET | Source: Codex DNA, Inc.

Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021...
February 24, 2022 08:03 ET | Source: Codex DNA, Inc.

Codex DNA to Present at the Cowen 42nd Annual Healthcare Conference

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief...
February 09, 2022 08:03 ET | Source: Codex DNA, Inc.

Codex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that members of its management team will be...
January 18, 2022 08:03 ET | Source: Codex DNA, Inc.

Codex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics

Proprietary short oligo ligation assembly (SOLA) technology used to enzymatically synthesize DNA fragments for the construction of full-length H1 and N1 genes from influenza A virusInitial performance...
January 10, 2022 06:50 ET | Source: Codex DNA, Inc.

Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Development of mRNA-based Vaccines and Biotherapies

Pfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA’s novel enzymatic DNA synthesis (EDS) technologyPfizer’s successful development and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right